Overview
A Study With Ruxolitinib Phosphate Cream Applied Topically to Subjects With Alopecia Areata (AA)
Status:
Terminated
Terminated
Trial end date:
2017-10-03
2017-10-03
Target enrollment:
0
0
Participant gender:
All
All
Summary
A phase 2 study to find out if the drug ruxolitinib Phosphate Cream is safe and has beneficial effects in people who have alopecia areata (partial or complete hair loss) when applied to the skin.Phase:
Phase 2Accepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Incyte Corporation
Criteria
Inclusion Criteria:- Diagnosis of AA
- Duration and extent of current episode of AA
- Evidence of active hair loss
Exclusion Criteria:
- Evidence of diffuse, spontaneous terminal hair regrowth
- Receipt of treatment known to potentially affect the course of AA within last month